A prespecified secondary analysis of a randomized, double-blind, placebo-controlled trial examined vascular and inflammatory measurements in 108 adults with HIV and lipohypertrophy. The authors report that Semaglutide did not significantly change the study’s subclinical vascular markers over 32 weeks. They did report relative differences in a calculated 10-year ASCVD risk score and high-sensitivity C-reactive protein, or hsCRP.
The distinction between those findings matters. A calculated risk score and an inflammatory biomarker are not the same as observed long-term cardiovascular events. The trial also did not detect a significant difference for the arterial stiffness, endothelial-function, or coronary-calcium measures it used. This is a small, short secondary analysis, not evidence for an individual-level prediction or a protocol for human use.
What the secondary analysis measured
The trial enrolled adults with virologically suppressed HIV, stable antiretroviral therapy, no known diabetes, increased central adiposity, and a body-mass index above 25. Participants were randomized 1:1 to Semaglutide or placebo for 32 weeks. The cardiovascular analysis was prespecified rather than added after the study results became available.
Investigators used pulse-wave velocity to assess arterial stiffness, peripheral arterial tonometry to assess endothelial function, and coronary artery calcium scoring to assess calcified coronary atherosclerosis. They also measured resting energy expenditure and oxygen consumption. These are intermediate or subclinical measures. They do not directly report future cardiovascular-event rates.
The measures that did not differ significantly
In the published analysis, Semaglutide showed no significant effect on pulse-wave velocity, coronary calcium score, reactive hyperaemia index, augmentation index, or resting energy expenditure during the 32-week comparison. Oxygen consumption showed a downward trend, but the reported P value did not meet conventional statistical significance.
This negative pattern is as informative as the positive secondary findings. It shows that the measured vascular indicators did not all move together, even though the original trial had already reported changes in body composition and metabolic measures. The study therefore does not support treating one change in a calculated score as proof of changed vascular structure or function.
Risk-score and inflammatory findings
At week 32, the authors report a 32.6% relative reduction in the 10-year ASCVD risk score and a 23.4% relative reduction in hsCRP for Semaglutide versus placebo. Both are results within this defined population and time frame. The ASCVD estimate is a model based on participant characteristics, while hsCRP is a circulating inflammatory marker.
Neither endpoint replaces a clinical-outcomes trial. The study contained 108 participants, with 54 assigned to Semaglutide, and followed them for 32 weeks. Larger studies with longer follow-up would be required to determine whether changes in these intermediate measures correspond to differences in cardiovascular events.
Why HIV-specific research needs careful framing
HIV, antiretroviral exposure, central adiposity, smoking, inflammation, and cardiovascular risk can interact in ways that differ from other trial populations. The authors selected a population with stable viral suppression and no known diabetes, so the findings cannot simply be applied to all people with HIV or to settings outside the trial.
The paper also does not compare Semaglutide with Retatrutide or Tirzepatide. These are separate compounds, and the study cannot provide an indirect ranking between them. For distinct compound background, see the Retatrutide research guide.
Peptra Labs materials remain within a Research Use Only boundary. The site’s research peptide risk profile also separates research discussion from claims about human use. This clinical trial did not test a Peptra Labs material.
The appropriate takeaway is narrow: in this 108-participant, 32-week secondary analysis, Semaglutide did not significantly alter the vascular markers measured by the investigators, while two cardiometabolic proxy measures differed from placebo. The result identifies a focused question for larger outcome studies, not a conclusion about cardiovascular events or individual use.
References
- Daher J, Koberssy Z, Moussallem N, et al. Effects of semaglutide on subclinical cardiovascular health in people with HIV. AIDS. 2026. PubMed
- ClinicalTrials.gov. Semaglutide in People with HIV and Lipohypertrophy, NCT04019197. Registry record
- Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV. Circulation. 2019. Article
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
